Rolf Bjerkvig (f. 1953) is Professor for cell biology and has since the ealy 80s worked in experimental cancer biology.
Bjerkvig is Director of the Kristian Gerhard Jebsen Brain Tumor Research Center, located at the Department of Biomedicine. He is director of the Oncology Department at the Luxembourg Institute of Health, and has established the NORLUX Neuro-Oncology network.
Dr Bjerkvig receives major grants from the Norwegian Research Council, The Norwegian Cancer Society and the European Commission. He is on the editorial board on several international journals and is sitting in several national as well as international funding committees for cancer research in Europe. He has published more than 200 articles in scientific literature and has received a number of research prizes for his work. In 2015, Bjerkvig was awarded the King Olav V Research Prize in Cancer Research.
- 2019. Therapeutic effect of cabazitaxel and blood-brain barrier opening in a patient-derived glioblastoma model. Nanotheranostics. 103-112.
- 2019. Stem cell-associated heterogeneity in Glioblastoma results from intrinsic tumor plasticity shaped by the microenvironment. Nature Communications.
- 2019. Peptide-guided nanoparticles for glioblastoma targeting. Journal of Controlled Release. 109-118.
- 2019. Mutant IDH1 Differently Affects Redox State and Metabolism in Glial Cells of Normal and Tumor Origin. Cancers.
- 2019. Interfering with long non-coding RNA MIR22HG processing inhibits glioblastoma progression through suppression of Wnt/β-catenin signalling. Brain.
- 2019. Effective treatment of metastatic melanoma by combining mapk and pi3k signaling pathway inhibitors. International Journal of Molecular Sciences. 1-19.
- 2019. Deep sequencing of a recurrent oligodendroglioma and the derived xenografts reveals new insights into the evolution of human oligodendroglioma and candidate driver genes. OncoTarget. 3641-3653.
- 2019. Blood brain barrier opening and Therapeutic Effect of Free and Nanoencapsulated Cabazitaxel in an Invasive Patient-Derived Glioblastoma Model.
- 2019. Bi-specific tenascin-C and fibronectin targeted peptide for solid tumor delivery. Biomaterials. 1-11.
- 2019. A new chance for EGFR inhibition in glioblastoma? Neuro-Oncology. 1487-1488.
1987: Dr. philos. The Gade Institute of Pathology, University of Bergen
1981: M.Sc. Immunology, University of San Francisco, 1981.